Answers are grounded in this paper and cite their sources.
Deep brain stimulation (DBS) alleviates Parkinson's disease (PD) symptoms, but its immunomodulatory mechanisms remain elusive. Through integrating microarray (GSE23676), single cell/nucleus RNA-seq (GSE184950, GSE202210, GSE223138, GSE243639; after quality control (mitochondrial gene content <25%, gene number >200) 616,076 high-quality cells were included), and GWAS data, we identified CLIC3 as a DBS-associated, potential protective implications in PD. CLIC3 was selectively up-regulated in a distinct natural killer cell subset (NK_CLIC3), which secreted TGFB1 to restrain neuroinflammation. CellChat and immunohistochemistry revealed that NK_CLIC3 cells communicated with PD-relevant neuronal populations: excitatory (SLC18A2+), inhibitory (SLC18A2+), oligodendrocyte (SLC18A2+), and astrocytic (SLC18A2+) cells via THY1–ADGRE5 and GZMA–PARD3 axes. Immune infiltration analysis (GSE114517; n = 75) suggested NK infiltration and deficient M2 macrophage recruitment in PD brains, underscoring an inadequate anti-inflammatory response. We further isolated CLIC3-positive NK cells (from a healthy donor) by fluorescence-activated cell sorting (FACS) and confirmed their ability to degrade α-synuclein, the pathological protein in Parkinson's disease, supporting the potential NK(CLIC3+) cells' protective function in PD. Our findings suggest DBS may expand NK_CLIC3 cells to suppress neuroinflammation through TGFB1 mediated immune–neuronal crosstalk, positioning CLIC3 as a prospective therapeutic target for PD.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: